Viridian Therapeutics, Inc. (0K1R.L) LSE

18.65

+0.1476(+0.80%)

Updated at September 08 02:34PM

Currency In USD

Viridian Therapeutics, Inc.

Address

221 Crescent Street

Waltham, MA 02453

United States of America

Phone

617 272 4600

Sector

Healthcare

Industry

Biotechnology

Employees

143

First IPO Date

January 29, 2018

Key Executives

NameTitlePayYear Born
Mr. Stephen F. Mahoney J.D., MBAChief Executive Officer, President & Director652,7041971
Mr. Thomas W. Beetham J.D., MBAChief Operating Officer517,0001970
Mr. Seth HarmonChief Financial Officer552,4671981
Ms. Jennifer Tousignant J.D.Chief Legal Officer611,9511973
Dr. Eric N. Olson Ph.D.Co-Founder & Chairman of Scientific Advisory Board0N/A
Ms. Melissa MannoChief Human Resources Officer0N/A
Mr. Vahe Bedian Ph.D.Co-Founder & Scientific Advisor0N/A
Mr. Anthony CascianoChief Commercial Officer01977
Dr. Michael R. Bristow M.D., Ph.D.Co-Founder & Member of the Scientific Advisory Board01945
Dr. Marvin H. Caruthers Ph.D.Co-Founder & Scientific Advisory Board Member01940

Description

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.